Table 3. Competing risk proportional hazard regression analyses of time to therapeutic progression.

	Addition of an antidiabetic medicine or switch to insulin					Addition of an antidiabetic medicine or switch to any antidiabetic medicine
	SHR	95% CI		P value		SHR		95% CI		P value
Number of unrelated comorbidities	0.872	0.839–0.905		<0.001		0.879		0.852–0.907		<0.001
Cancer	0.703		0.590–0.836		<0.001		0.690		0.605–0.788		<0.001
Chronic obstructive pulmonary disease	0.866		0.778–0.963		0.008		0.855		0.786–0.930		<0.001
Dementia	0.682		0.519–0.895		0.006		0.636		0.512–0.791		<0.001
Depression	0.803		0.742–0.868		<0.001		0.781		0.734–0.832		<0.001
Urinary incontinence	0.794		0.542–1.164		0.237		0.752		0.555–1.02		0.067
Parkinson's disease	0.565		0.457–0.698		<0.001		0.635		0.544–0.742		<0.001
Age	0.975	0.972–0.977		<0.001		0.981		0.978–0.983		<0.001
Number of hospitalisations	0.776	0.744–0.809		<0.001		0.811		0.788–0.834		<0.001
Adherence to antidiabetic medicines	0.599	0.556–0.644		<0.001		0.545		0.513–0.579		<0.001
Residency (aged care versus community)	0.892	0.853–0.934		<0.001		0.884		0.849–0.920		<0.001
Endocrinology service	1.196	1.145–1.250		<0.001		1.317		1.269–1.367		<0.001

SHR, Subdistribution Hazard Ratio from multivariable competing risk regression analyses.